The determination of the viability and drug sensitivity of My cobacterium leprae in laboratory conditions has been a major problem, on account of the difficulty of growing this organism in vitro. To date the growth in the fo otpad of mice by the innoculated M. leprae, developed by Shepard1 8 and later modified by Rees,17 serves as the only recognized method to determine the viability of the organism, as well as evaluating the potency of anti leprosy drugs. The major drawback of the mouse fo otpad test is that it is time-consuming and thus unsuitable for large numbers of tests or experiments involving several new compounds. However, several in vitro test systems to demonstrate viability and drug sensitivity of M. leprae have been described recently. They include the 3 H-thymidine incorpora tion method, 1 5,14 ATP quantitation method, 4 DOPA uptake system, 2 Fc receptor assay system. 3,6, 1 2 Several other metabolic precursors have also been suggested as tools for determining viability of M. leprae. They are hypoxanthine, and amino acid;8,9 labelled acetate. 19
My cobacterium leprae was obtained from infected armadillo tissues or human biopsies fr om untreated or partially treated lepromatous leprosy patients. Macrophages were fr om the peritoneal cavity of Swiss white mice. The preparations of both these components have been described in detail in our earlier publications.6,1 2
The Fc receptor assay system, using EA rosetting technique in relation to viability of M. leprae was described by Birdi et al.3 using macrophages from humans. This was further adapted by using macrophages from peritoneal cavity of Swiss white mice. 1 2 The assay system is described in Table 1 . J agannathan and Mahadevan6 had clearly demonstrated that dapsone, a drug used for in vitro assay systems, enters macro phages and the concentration inside the macrophages could be estimated in the solvent extracted sample by spectrofluorimetry. Information background: The number of macrophages with Fc receptors is lowered by live M. /eprae after their phagocytosis and it is unaltered by heat-killed M. /eprae when compared to normal macrophages. 3 This assay system was adopted using M. leprae phagocytosed by macro phages and was described earlier. 16 The basic steps in this assay system are given in Table  2 . Further details on this method are under publication (Bhagaria and Mahadevan communicated).
Uracil up take assay
The test system using the uptake of labelled uracil by M. leprae inside the macrophages has been described earlier (Vejare and Mahadevan, under publica tion). The broad details are presented in Table 3 . 
Sialic acid assay system
The alteration in surface sialic acid due to viable bacteria inside the macro phages fr om patients has been reported.] The basic steps involved in the assay have already been published.]
EXPERIMENTAL RESULTS

Fc receptor assay system
That the M. leprae phagocytosed by macrophages are susceptible to drugs like dapsone and rifampicin is shown by the data presented in Tables 4 and 5 respectively. M. leprae in presence of drugs are unable to bring down the level of macrophages with Fc receptors but only live M. leprae are able to do so. The minimum inhibitory concentration effective in this assay system for dapsone is 0·028 I1g/ml (28 ng/ml) and for rifampicin O·ll l1g/ml (1 14 ng/ml) ( Tables 6 & 7) . Since the determination of EA rosetting is a subjective procedure, the technique of using ] 2 51 labelled anti SRBC was adopted. The data presented in Tables 8 and 9 clearly show that this technique also shows the reduction in EA rosetting macrophages is quite clear in presence of live M. leprae and reversed in presence of anti-leprosy drug and M. leprae. In presence of live M. leprae, lesser amounts of labelled antibody bind to macrophages and this is reversed in presence of the drug with the M. leprae.
Lastly, using this assay system the viability of M. leprae exposed to dapsone and rifampicin in the macrophages, were determined in mouse fo otpad. It clearly showed that those M. leprae exposed to drugs and showing viability to lower the Fc receptors, also showed a poor growth in the mouse fo otpad. This indicated loss of viability by the M. /eprae in presence of the drug inside the macrophages (Figures 2 and 3) . The drug DDS showed that it acted clearly as bacteriostatic, since the M. /eprae after removal fr om the drug-containing macrophage did show viability in mouse fo otpad. The rifampicin- (Figure 3 ) treated M. /eprae showed loss of viability.
FDA-EB ASSAY SYSTEM
Data presented in Figure 4 show that in the presence of the anti-M. leprae drug dapsone the ability of M. leprae to break down FDA and express green fluorescence of the Fluorescein is drastically reduced. This could be due to the loss of viability in presence of the drug. A typical experimental result using this assay system with rifampicin is presented in Table 10 .
Since determination of fluorescing M. leprae is a subjective experimental procedure, we have adopted estimation of fluorescence by viable M. leprae by Control, M. leprae added culture significant p < 0·05; M. leprae only, drug + M. leprae significant p < 0·05. Each value is an average of fo ur experiments with each concentration of the drug added. A-B, P < 0·05 significant; A-C, P < 0·05 significant; A-D, P < 0·05 significant up to 15 ng only; A-E, P> 0·05 not significant; A-D, P < 0·05 significant above 15 ng only.
* Minimum inhibitory concentration (MIC). The dose of M. /eprae, 5 x 106/Leighton tube.
DDS dose-O·03 pg/ml-MIC level with Fc receptor system. spectrofluorometry. Data presented in Table 11 show that with treatment of M. leprae inside the macrophages with rifampicin 0'14 J.lg/ml) the FDA degrading the fluorescing bacteria come down as indicated by reduction in the fluorescence level at an excitation wavelength of 485 nm and emission wavelength of 520 nm in the fluorimeter. Lastly to show that the bacteria whose viability after rifampicin treatment was low, by FDA assay, were also tested in mouse fo otpad. The growth patterns of drug untreated M. leprae and drug treated M. leprae are presented in Figure 5 . AFB, acid-fast bacteria; GFB, green fluorescing bacteria . This clearly indicated that what appear as non-viable bacteria after RFP treatment by FDA test, also showed no viability in the mouse fo otpad.
URACIL UPTAKE SYSTEM
We had already demonstrated that uracil is taken up by free M. leprae and M. /eprae inside the macrophages. We had also demonstrated that per unit amount of M. /eprae more labelled uracil is taken up while the bacteria are inside the macrophages, as compared to the freely suspended bacteria (Vejare and Mahadevan, under publication). Observations reported in Table 12 show uptake of uracil by M. /eprae inside the macrophages and this could be expressed as dpm/ l x 106 M. leprae. This uptake was blocked in presence of rifampicin (Table 12) indicating that the drug sensitivity of M. leprae could be determined using this metabolic activity of M. leprae inside the macrophages.
SIALIC ACID ASSAY SYSTEM
We had reported that in the macrophages from bacillary negative lepromatous leprosy patients, live M. leprae induce a lowering of surface sialic acid. I This observation is also borne out by data presented in Table 13 . This alteration of sialic acid level by M. leprae was shown to be both host and bacteria specific. Heat killed M. leprae were not able to do so. Thus, extrapolating this information we have also demonstrated that if viability of M. /eprae is reduced by rifampicin (5 fig/ml) inside the macrophages, then they also lose the ability to reduce the surface sialic acid level of macrophages. Incorporation is expressed as dpm/I x 106 M. leprae. 
NEW COMPOUNDS-ANTI-M. LEPRAE ACTIVITY
If the above in vitro assay systems are useful to determine viability and drug sensitivity of M. leprae then new compounds could be screened for activity against M. leprae using these test systems. If they are fo und to be active against M. leprae, they should also show activity against M. leprae in the mouse fo otpad assay system. We present data to show the activity of a few compounds against M. leprae using the Fc receptor assay system and also the FDA test. The compounds tested were Deoxyfructoserotonin, Brodimoprim (in combination with DDS), ciprof loxacin, methyoxy-2-Indole-derivative and Folate analogues, and K. 130 in (Tables 14, 15 
Discussion
The methods adopted for determining viability of M. leprae by us have been based on the behaviour of M. leprae and the host cell (macro phages) when they are together. None of the test systems depend on the necessity of mUltiplication of M. leprae. But they depend on the expression of the metabolic activity of M. leprae (FDA assay, uracil uptake) or changes introduced by the pathogen-host interaction in the host cell (Fc receptor changes, sialic acid change). It is clear fr om the data presented on the effect of drug on these parameters, that there is a definite MEC (minimum effective concentration) in all these cases. It was shown to be 0·028 jig/ml for DDS and 0· 11 jig/ml rifampicin in Fc receptor assay system and 0· 1 jig/m!. DDS and 0· 17 jig/ml rifampicin in FDA assay system (Jagan nathan & Mahadevan, 1986, Bhagaria & Mahadevan, under preparation). Thus it is clear that the phenomenon observed is basically an actual event which is controlled by the level of drug exposed to M. leprae.
Further it has been demonstrated when loss of viability of M. leprae was indicated in presence of the drug in the Fc receptor assay system (inability to reduce EA rosetting macrophages). Such M. leprae had also shown loss of viability through their inability to hydrolyse FDA and consequent fa ilure to exhibit green fluorescence. There is correlation between the two in vitro methods. The fundamental correlation of loss of viability of M. leprae inside the macrophages in presence of drug and as determined by Fc receptor or FDA assay was the demonstration that such M. leprae showed no growth or at best poor growth in the mouse fo otpad. The M. leprae prepared in a similar way from macrophages without drug treatment showed good viability.
The routine procedure of using microscope and determining either fluores cence of the bacteria or rosetting macro phages was fo und to be a valid technique, since the observations obtained were correlated with spectrofluorimetric measurements or 1 2 51 labelled antibody binding to Fc receptors in the respective tests mentioned above.
Thus it is very clear that we have demonstrated new in vitro assay systems capable of determining drug sensitivity and viability of M. leprae in less than lO IS days. Consequently one should be able to determine the potentiality ofanti-M.
leprae nature of some new compounds. We have been able to do these kind of tests and have identified the fo llowing compounds as active against M. leprae: 1, Deoxyfructoserotonin; 2, 1ndole-2-methoxy compound; 3, Diflunisal (Merck, Sharp and Dohme); 4, Ciprofloxacin (Bayer); 5, Brodimoprim alone or in combination with DDS (Dr J K Seydel); and 6, K-130 (Dr J K Seydel).
Leprologists will accept efficacy of these drugs if they could be demonstrated to show activity against M. leprae infected in mice. The role of mouse metabolism preferentially inactivating the drug or poor pharmacokinetics in mice can lead to wrong data. But this is ignored.
Nevertheless if correlation comes, everybody is satisfied. Thus anti-M. leprae activity against M. leprae in mice has been shown for deoxyfructoserotonin,1 3 We are now in the process of testing ciprofloxacin, diflunisal and Indole-2-methoxy compounds in the mouse fo otpad system in our laboratory.
It would be worthwhile to note, fo llowing the in vitro assay system in our laboratory, that DFS was identified as anti-M. leprae 2 ,7 and later confirmed in mouse fo otpad and is now in clinical trial in Bombay, India. This should be considered as a unique success in the drug development programme against leprosy. This success opens up vast potential for exploitation of the lead shown by the in vitro assay system developed in our laboratory.
The advantages of these in vitro assay systems are: (a) it is completed in less than 10-12 days; (b) in vitro MIC can be determined; (c) synergistic activity between two different drugs can also be established; and (d) static or cidal effect can be assessed. Among the drawbacks: (a) one needs at least 5-10 million M. leprae for each assay as compared to 1 x 10 4 in mouse fo otpad; and (b) as patients improve on drug therapy, viability goes down and thus to monitor the viability one has to use higher numbers of bacilli and this may lead to ambiguous information.
Nevertheless, we are in a position now to identify potential anti-M. leprae compounds much fa ster than we were 5 years ago. This is a definite advance in drug research in the area of leprosy control.
